BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Cerexa to be acquired by Forest Laboratories for $480 million plus potential $100 million milestone payment
News | 12. 14. 2006
Cerexa
Cerexa Inc. today announced it has entered into a definitive agreement to be acquired by Forest Laboratories Inc. (NYSE: FRX) for $480 million plus a potential $100 million milestone payment.
